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Rheumatoid arthritis (RA) is an autoimmune disease caused by inflammation of the
synovium and characterized by chronic polyarthritis that destroys bone and cartilage.
Fibroblast-like synoviocytes (FLSs) in the synovium of patients with RA can promote
cartilage and bone destruction by producing proteins such as matrix metalloproteinases
and receptor activator of NF-κB ligand, thereby representing an important therapeutic
target for RA. FLSs have several phenotypes depending on which cell surface proteins
and adhesion factors are expressed. Identifying the cellular functions associated with
different phenotypes and methods of controlling them are considered essential for
developing therapeutic strategies for RA. In this study, synovial tissue was collected
from patients with RA and control subjects who required surgery due to ligament
injury or fracture. Immunohistological analysis was used to investigate the rates of
positivity for phosphorylated platelet-derived growth factor receptor-αβ (pPDGFRαβ) and
cadherin-11 (CDH11) expression, and apoptosis-related markers were assessed for
each cell phenotype. Next, FLSs were isolated in vitro and stimulated with tumor necrosis
factor-α (TNF-α) in addition to a combination of PDGF and transforming growth factor
(2GF) to investigate pPDGFRαβ and CDH11 expression and the effects of the inhibition
of TNF and cyclin-dependent kinase (CDK) 4/6 on FLSs. Immunohistological analysis
showed a large percentage of pPDGFRαβ+CDH11– cells in the sub-lining layer (SL)
of patients with RA. These cells exhibited increased B-cell lymphoma-2 expression,
reduced TNF receptor-1 expression, resistance to cell death, and abnormal proliferation,
suggesting a tendency to accumulate in the synovium. Further, in vitro 2GF stimulation
of FLSs lowered, whereas 2GF + TNF stimulation increased the pPDGFRαβ/CDH11
ratio. Hypothesizing that FLSs stimulated with 2GF + TNF would accumulate in vivo
in RA, we determined the therapeutic effects of TNF and CDK4/6 inhibitors. The TNF
inhibitor lowered the pPDGFRαβ/CDH11 ratio, whereas the CDK4/6 inhibitor suppressed
cell proliferation. However, a synergistic effect was not observed by combining both
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the drugs. We observed an increase in pPDGFRαβ+CDH11– cells in the SL of the RA
synovium and accumulation of these cells in the synovium. We found that the TNF
inhibitor suppressed FLS activity and the CDK4/6 inhibitor reduced cell proliferation.
Keywords: rheumatoid arthritis, chronic inflammation, fibroblast-like synoviocyte, cadherin-11, platelet-derived
growth factor receptor, apoptosis
INTRODUCTION
Rheumatoid arthritis (RA) is an idiopathic form of arthritis that is
both chronic and progressive and undergoes repeated stages of
remission and flare-up (1). Advances in pharmacotherapies, such
as with immunosuppressants and biological drugs, have raised
remission rates, although inducing remission remains difficult in
30–40% of patients with RA, and joint destruction can progress
even in remission (2). Moreover, flare-ups tend to occur when
pharmacotherapy is halted, rendering it difficult to suspend
medication. A fundamental therapy for RA is still lacking (3).
In previous studies on RA patients and RA model animals, the
accumulation of fibroblast-like synoviocytes (FLSs) in the joint
synovium was reported as the primary cause of joint destruction
(4, 5). Cells in the synovium are categorized morphologically
as macrophage-like cells with non-fixed phagocytic capacity and
FLSs, which have spindle shapes and form regular networks (6).
There are several FLS phenotypes, including the expression of
cell-adhesion factors cadherin-11 (CDH11) and gp38, as well
as CD90, CD248, and others proteins that are also expressed
as surface antigens on regular fibroblasts (7, 8). Among these,
CDH11 is expressed in the lining layer (LL) and sub-lining layer
(SL) of the synovium (9). FLSs in the LL produce a particularly
large amount of matrix metalloproteinases (MMPs), which are
known as the main agents of joint destruction, and are thus
important therapeutic targets (4, 7, 10, 11). At present, one
of the most effective drugs are tumor necrosis factor (TNF)
inhibitors, the therapeutic mechanism of which is reported to
be suppressing inflammation by reducing FLS influx into the
LL (9). Nonetheless, TNF inhibitor therapy has little effect on
FLSs in the SL (9) and has even been reported to cause fibrosis
of the SL (12). Therefore, improving SL-FLS accumulation is
thought to be difficult with existing therapies (13). Moreover,
compared to the LL, the SL has more blood vessels, lymphocytes,
plasma cells, and macrophages and is considered as a center
of synovial inflammation (10). Therefore, gaining a deeper
understanding of SL-FLS phenotypes and establishing methods
of controlling them could help to develop novel therapies
for RA.
Tissue fibrosis accompanying intractable chronic
inflammation is associated with increased platelet-derived
Abbreviations: RA, rheumatoid arthritis; FLSs, fibroblast-like synoviocytes;
CDH11, cadherin-11; LL, lining layer; SL, sub-lining layer; MMPs, matrix
metalloproteinases; TNF, tumor necrosis factor; PDGF, platelet-derived growth
factor; Bcl-2, B-cell lymphoma 2; HE, hematoxylin and eosin; PBS, phosphate-
buffered saline; BSA, bovine serum albumin; RT, room temperature; ICCs,
intraclass correlation coefficients; PSL, prednisolone; MTX, methotrexate; CAFs,
cancer-associated fibroblasts; EMT, epithelial-mesenchymal transition; ECM,
extracellular matrix.
growth factor (PDGF) signaling and the proliferation
and accumulation of PDGF receptor (PDGFR)-positive
mesenchymal cells or fibroblasts in various organs, including
the kidneys, liver, myocardium/skeletal muscle, and bone
marrow (14–16). The synovium of RA patients has been
reported to exhibit greater expression of phosphorylated
PDGFRαβ (pPDGFRαβ), an activated form of PDGFR,
than the synovium of osteoarthritis patients (17). PDGF
signaling promotes cell survival and cell proliferation
via the PI3K–At pathway and Ras–MAPK pathway (14),
which strongly suggests that FLSs with a treatment-
resistant, aggressive phenotype that accumulate in RA
are pPDGFRαβ-positive. Therefore, this study aimed to
investigate pPDGFRαβ expression in FLSs accumulated
in the synovium during RA and to clarify their locations,
phenotypes, and signals related to cell survival and
cell death.
In this study, pPDGFRαβ-positive cells that proliferate
specifically in the SL of RA exhibited low expression of TNF-
receptor-1 (TNF-R1) and the cell-cycle suppressor p16, as well
as high expression of B-cell lymphoma 2 (Bcl-2), which confers
resistance to cell death. We also investigated resistance to cell
death after increased pPDGFRαβ expression in FLSs through
in vitro stimulation with PDGF-BB, TGF-β, and TNF-α, as well as
candidate drugs for pPDGFRαβ-positive cells. We propose that a
new therapeutic strategy can potentially be developed for RA by
targeting pPDGFRαβ+CDH11– cells.
MATERIALS AND METHODS
Patients and Tissue Samples
Experiments using human samples were approved by the
institutional review board at the Sapporo Medical University
(approval no., 292-3303), and all experiments were performed
in accordance with relevant guidelines and regulations. Synovial
tissues were obtained from patients undergoing arthroscopic
or arthroplastic surgery at the Sapporo Medical University
or Sapporo Maruyama Orthopedics Hospital, after informed
consent was obtained from the patients. All subjects provided
written informed consent in accordance with the Declaration of
Helsinki. Twenty-five patients with RA fulfilling the American
College of Rheumatology (ACR; formerly, the American
Rheumatism Association) criteria were included in this study.
In addition, 13 patients who required arthroscopic surgery for
ligament injury or fracture were included as control patients
with acute inflammation. Acute inflammation was defined as that
occurring less than 8 weeks after injury, as in previous studies
(18). The clinical features of the patients who donated samples
are summarized in Table 1.
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TABLE 1 | Characteristics of patients with RA and acute inflammation (control
subjects).
RA Control
N = 25 N = 13
Age (years) 58.2 (25–83) 36.6 (20–61)
Gender (% female) 89% 31%
Disease duration 11.7 (1–40) years 19.8 (3–56) days
Treatment Prednisolone 15 (63%) –
Methotrexate 8 (33%) –
Biological drugs 8 (33%) –
ACPAs, positive patients (%) 11/14 (79%) –
RF, positive patients (%) 18/23 (82%) –
CRP (mg/dL) 1.3 (0.1–5.8) –
MMP3 (ng/mL) 206.2 (53–596) –
ACPAs, anti-citrullinated protein antibodies; control, trauma patients; CRP, C-reactive
protein; MMP3, matrix metalloproteinase 3; RA, patients with rheumatoid arthritis; RF,
rheumatoid factor.
Immunohistochemistry of Tissues
For immunohistochemistry studies, tissues were fixed in 4%
paraformaldehyde overnight. The following day, the tissues were
transferred to 20% sucrose in phosphate buffer and incubated
overnight, frozen in OCT compound by using liquid nitrogen,
and stored at −80◦C until use. Cryosections (8-µm thick)
were prepared using a cryostat. The sections were stained with
hematoxylin and eosin (HE). For immunohistochemistry, the
sections were incubated in 0.01M phosphate-buffered saline
(PBS) containing 0.3% Triton-X (PBS-T) and 2% bovine serum
albumin (BSA) for 60min at room temperature (RT). After the
sections were washed with 0.01M PBS-T, they were incubated
with primary antibodies at 4◦C overnight, followed by staining
with secondary antibodies. Staining was performed using
primary antibodies against anti-pPDGFRα(Tyr849)/β(Tyr857;
1:75; Cell Signaling Technology, Danvers, MN, USA), anti-
cadherin-11 (15µg/mL; R&D Systems, Minneapolis, MN, USA),
TNF-R1 (1:500; Thermo Fisher Scientific, San Diego, CA,
USA), Bcl-2 (1:50; BD Biosciences, Franklin Lakes, NJ, USA),
p16 (1:200, Abcam, Cambridge, UK), and p53 (1:50; Santa
Cruz Biotechnology, Santa Cruz, CA, USA), CD45 (1:1000;
Abcam). For secondary antibodies, we used Alexa Fluor 488-
conjugated IgG (1:100; Jackson ImmunoResearch, West Grove,
PA, USA), Alexa Fluor 647-conjugated IgG (1:100; Jackson
ImmunoResearch), and Cy3-conjugated IgG (1:100; Merck
Millipore, Darmstadt, Germany). Nuclei were stained using 4′6-
dimidino-2-phenylindole (DAPI; 1:1000; Dojindo, Kumamoto,
Japan). Sections were observed using a confocal laser scanning
microscope (Nikon/A1; Nikon, Tokyo, Japan) and fluorescence
microscopy (BZ-X800, Keyence Corp., Osaka, Japan). NIS
elements (Nikon) and BZ-X800 analysis application (Keyence
Corp.) were used for cell analysis. Images were acquired from
eight different regions of each tissue section. Settings for one
staining experiment were maintained across all experiments.
LL and SL were distinguished by morphology for each region
by using low-magnification imaging. The cell depth of the LL
was assessed for 3 regions of each high-power field of the
synovium, and the LL thickness was expressed as the mean
number of cells in depth. High-magnification imaging was used
to confirm the identity and analyze the distribution of cells.
DAPI staining was used to count separately pPDGFRαβ-positive
and CDH11-positive cells and classify cells into three groups
as follows: pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, and
pPDGFRαβ+CDH11+ cells; next, the relative abundance of
each cell type was evaluated. Similarly, cells positive for TNF-
R1, Bcl-2, p16, p53, or CD45 expression were counted. Briefly,
we classified cells into pPDGFRαβ+CDH11–, pPDGFRαβ-
CDH11+, and pPDGFRαβ+CDH11+ cells by overlay image
of DAPI filter channel (excitation 360 nm, emission 460 nm;
DAPI), GFP filter channel (excitation 470 nm, emission 525 nm;
CDH11) and Cy5 filter channel (excitation 620 nm, emission
700 nm; pPDGFRαβ); next, the TRITC filter channel (excitation
545 nm, emission 605 nm; TNF-R1, Bcl-2, p16, p53 and CD45)
image was overlayed on the overlay image of DAPI, GFP and
Cy5 filter channel to evaluate cells positive for TNF-R1, Bcl-
2, p16, p53 and CD45 in pPDGFRαβ+CDH11–, pPDGFRαβ-
CDH11+, and pPDGFRαβ+CDH11+ cells. Two researchers
independently assessed the number of cells positive for each
marker. Intraclass correlation coefficients (ICCs) for pPDGFRαβ
and CDH11 reflected good (ICC= 0.82) internal consistency.
Cell Preparation and Cell Proliferation
Assays
Synoviocytes were isolated from synovial tissue by using standard
procedures (19). Synoviocytes from patients with RA were
digested with Liberase TM Research Grade (Sigma–Aldrich)
for 90min at 37◦C. The digested synoviocyte slurries were
filtered through a 100µm cell strainer (EASYstrainerTM Cell;
Greiner Bio-One, Kremsmünster, Austria). Cells were suspended
in the growth medium consisting of Dulbecco’s modified Eagle’s
medium (Sigma–Aldrich) supplemented with 10% fetal bovine
serum, 100 U/mL penicillin, and 100µg/mL streptomycin and
incubated at 37◦C in 5% CO2. Cells at passages 3 to 6 were used
in all experiments.
For cytokine stimulation, cells were treated with or without
various concentrations (1, 10, and 100 ng/mL) of PDGF-BB
(BioLegend; San Diego, CA, USA), TGF-β (BioLegend), or TNF-
α (BioLegend) for 2 days, as per our approved experimental
design. The role of therapeutic drugs was determined by
treating cells stimulated with cytokines with 10, 25, or 50µg/mL
etanercept (Pfizer, NY, USA) or 7.5µM or 15µM palbociclib
(Sigma–Aldrich), or a combination of 25µg/mL etanercept and
7.5µM palbociclib for 1 day, as per our experimental design.
These doses of cytokines and inhibitors were selected based on
the findings of previous studies (20–23). WST-8 assays were




Cells were cultured in 96-well plates and treated with
various concentrations of PDGF-BB, TGF-β, and/or TNF-
α in combination with palbociclib and/or etanercept for 2
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FIGURE 1 | Accumulation of pPDGFRαβ+CDH11– cells in the sub-lining layer (SL) of the synovium in rheumatoid arthritis (RA). (A) HE staining of the synovial tissue
collected from patients with RA and control subjects. Thickening of the lining layer (LL) and an elevated cell count in the SL were observed in RA. (B) the RA group’s
LL exhibited an increased cell depth, (C) and the cell count was elevated in the SL. (D) representative images of pPDGFRαβ and CDH11 staining of synovial tissue
(Continued)
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FIGURE 1 | from controls and patients with RA, and quantitative data on 3 cell populations (pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, and pPDGFRαβ+CDH11+
cells). The dotted line shows the margin of LL. (E–G) the percentages of pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, and pPDGFRαβ+CDH11+ cells in the LL did
not differ between the RA and control groups. (E–G) the percentage of pPDGFRαβ+CDH11– cells in the SL was significantly higher in the RA group than in the control
group (P = 0.019). The quantitative data show the percentages of pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, and pPDGFRαβ+CDH11+ cells out of the total
number of cells. An unpaired t-test was used for statistical analysis. The significance level was P < 0.05.
days. Cultured cells were fixed with 4% paraformaldehyde
for 15min at RT and then incubated in 2% BSA in PBS-
T for 60min at RT. After the cells were washed with PBS-
T, they were incubated for 2 h at RT with a primary Alexa
Fluor 488-conjugated anti-PDGFRA(Tyr849)/PDGFRB(Tyr857)
antibody (1:20; Bioss, Boston, MA, USA) and a primary APC-
conjugated anti-cadherin-11 antibody (1:80; BioLegend). Nuclei
were stained with DAPI (1:1000; Dojindo). The fluorescence
intensities of pPDGFRαβ and CDH11 staining were measured
using a microplate reader (INFINITE M1000 PRO; Tecan
Trading AG, Switzerland) and normalized based on the DAPI
staining intensity.
Statistical Analysis
Normality was assessed using the Shapiro–Wilk test. An unpaired
t-test was used to assess differences in the percentage of
pPDGFRαβ- and CDH11-positive cells between the control and
RA synovium. One-way analysis of variance was used to assess
percentage differences in histological cell staining under each
culture condition. The P-values for multiple comparisons were
adjusted using the Tukey–Kramer test. Pearson’s correlation
coefficient was used to assess the correlation. Dunnett’s test
was used to assess the concentration-dependent effect of each
inhibitor. Statistical analyses were performed using EZR, a
graphical user interface for R (The R Foundation for Statistical
Computing, Vienna, Austria) (24). Two-sided P-values less than
0.05 were considered statistically significant.
RESULTS
Accumulation of pPDGFRαβ+CDH11– Cells
in the SL of the Synovium of Patients With
RA
Immunostaining was performed to identify FLSs in the synovium
samples obtained during surgery from patients with RA (n =
25) and those having acute inflammation (n = 13). The mean
age of the patients with RA was 58.2 (25–83) years, and their
mean disease duration was 11.7 (1–40) years. The demographic
data, including drug history, of the patients are shown in Table 1.
HE staining was performed to compare the synovial tissues
between the RA and control groups. Compared to that in the
control group, increased LL thickening and excess cells in the SL
were observed in RA (Figures 1A–C, Supplemental Figure 1).
Differences between the RA and control groups regarding FLS
protein expression and location were determined by performing
immunostaining against CDH11 (5), a typical FLS marker, and
pPDGFRαβ, which increases specifically in the synovium of RA
and is positive in RA-FLS (17). Compared to control subjects,
patients with RA exhibited LL thickening and a clearly elevated
cell depth (Figures 1A,B), but no differences were noted in the
percentages of pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, or
pPDGFRαβ+CDH11+ cells (Figures 1D–G). In the SL, RA
exhibited a clearly elevated cell count (P < 0.0001; Figure 1C)
and an increased percentage of pPDGFRαβ+CDH11– cells (P
= 0.019; Figures 1D,E), but no differences were noted in the
percentages of pPDGFRαβ-CDH11+ or pPDGFRαβ+CDH11+
cells (Figures 1D,F,G). Whether the pPDGFRαβ+ cells are
of hematopoietic lineage was determined by performing
immunostaining against CD45, pPDGFRαβ, and CDH11 in the
SL; the percentage of CD45-positive cells per total cells was 33.9±
4.9% and that of cells double positive for CD45 and pPDGFRαβ
was 1.28± 1.2% (Supplemental Figure 2).
Characteristics of pPDGFRαβ+CDH11–
Cells Accumulating in the Synovium of
Patients With RA
The attributes of pPDGFRαβ+CDH11– cells accumulating in
the RA-SL were clarified by comparing the expression levels of
TNF-R1, Bcl-2, p16, and p53 between pPDGFRαβ+CDH11–,
pPDGFRαβ-CDH11+, and pPDGFRαβ+CDH11+ cells in the
RA-SL (Figure 2A). The TNF-R1, Bcl-2, p16, and p53 proteins
regulate cell death and cell proliferation (25, 26). Increased
expression of Bcl-2 and decreased expression of TNF-R1, p16,
and p53 are reported to induce tissue fibrosis through apoptosis
resistance and hyperproliferation (25, 26). The percentage of
TNF-R1-positive cells among pPDGFRαβ+CDH11– cells was
significantly lower than that among pPDGFRαβ+CDH11+
cells (P < 0.0001; Figure 2B). The percentage of Bcl-2-positive
cells was significantly higher among pPDGFRαβ+CDH11–
cells than among pPDGFRαβ-CDH11+ cells (P < 0.0001;
Figure 2B); in contrast, the percentage in pPDGFRαβ-CDH11+
cells was significantly lower than that in pPDGFRαβ+CDH11+
cells (P < 0.043; Figure 2B). The percentage of p16-positive
cells among pPDGFRαβ+CDH11– cells was significantly
lower than that among pPDGFRαβ+CDH11– cells and
pPDGFRαβ+CDH11+ cells (P = 0.013 and P < 0.0001,
respectively; Figure 2B). Significant differences were not
observed in the percentage of p53-positive cells. The above
findings show that pPDGFRαβ+CDH11– cells exhibited
low TNF-R1 and p16 expression and high Bcl-2 expression.
Further, the apoptotic and hyperproliferative features of
the three types of cells were better understood by performing
immunohistochemistry analysis in the RA and control synovium.
We found that Bcl-2 expression in RA was significantly
higher than that in the control in pPDGFRαβ+CDH11–,
pPDGFRαβ-CDH11+, and pPDGFRαβ+CDH11+ populations
(P = 0.0037, P < 00001, and P = 0.0012, respectively;
Supplemental Figure 3). In the RA group, the three types of cells
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FIGURE 2 | The pPDGFRαβ+CDH11– cells that accumulated in the SL of the synovium in RA exhibited reduced TNF-R1 and p16 expression and increased Bcl-2
expression. (A) representative staining images showing pPDGFRαβ, CDH11, TNF-R1, Bcl-2, p16, and p53 expression in the RA-SL. (B) quantitative expression data
for TNF-R1, Bcl-2, p16, and p53 in 3 cell populations (pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, pPDGFRαβ+CDH11+ cells). The percentage of TNF-R1-positive
(Continued)
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FIGURE 2 | cells among pPDGFRαβ+CDH11– cells was significantly lower than that among pPDGFRαβ-CDH11+ and pPDGFRαβ+CDH11+ cells. The percentage
of Bcl-2-positive cells among pPDGFRαβ+CDH11– cells was significantly higher than that among pPDGFRαβ-CDH11+ cells. The percentage of Bcl-2-positive cells
among pPDGFRαβ+CDH11+ cells was significantly higher than that among pPDGFRαβ-CDH11+ cells. The percentage of p16-positive cells among
pPDGFRαβ+CDH11– cells was significantly lower than that among pPDGFRαβ-CDH11+ and pPDGFRαβ+CDH11+ cells. p53 expression did not differ significantly
between the 3 cell populations. The quantitative data show the TNF-R1-, Bcl-2-, p16-, and p53-positive rates for the pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+,
and pPDGFRαβ+CDH11+ cells. One-way analysis of variance (ANOVA) was used for statistical analysis, and Tukey–Kramer method was used for intergroup
comparisons. The significance level was P < 0.05.
showed a significant difference; however, in the control group,
Bcl-2 expression was not markedly different among the three
types of cells. This suggests that pPDGFRαβ+ cells have more
anti-apoptotic property compared to CDH11-positive cells in
RA. In the control, p16 expression of the pPDGFRαβ+CDH11+
population was significantly higher than that of the other
cell types, and p16 expression in the pPDGFRαβ-CDH11+
population was higher than that in the pPDGFRαβ+CDH11–
population (pPDGFRαβ+CDH11+ > pPDGFRαβ-CDH11+ >
pPDGFRαβ+CDH11–; P < 0.0001 and P < 0.0001, respectively;
Supplemental Figure 3); this tendency was the same as that
in the RA group (Figure 2B). However, p16 expression in the
pPDGFRαβ+CDH11+ population in RA was significantly lower
than that of the control (P = 0.039; Supplemental Figure 3),
suggesting that the pPDGFRαβ+CDH11+ population of RA
might have greater proliferation capacity than in control.
Correlations Between the Therapeutic
Duration and Expression Rates of Various
Markers in Patients With RA
The relationships between RA patient characteristics and RA-
SL attributes were determined by investigating the correlations
of TNF-R1, pPDGFRαβ, and CDH11 expression with the
treatment duration and therapeutic agents. TNF-R1 expression
was not correlated with age (r = 0.042, P = 0.842; Figure 3A),
although it was negatively correlated with RA treatment
duration (r = −0.572, P = 0.0035; Figure 3B). The longer
the duration of RA treatment with prednisolone (PSL),
methotrexate (MTX), or biological drugs, the lower was
the expression of TNF-R1 in SL cells. TNF-R1 expression
was significantly lower following PSL therapy than after
MTX or biological drug therapy (P = 0.0113; Figure 3C).
However, TNF-R1 expression was not significantly different
between MTX and biological drug therapy (Figures 3D,E). The
percentage of pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+,
and pPDGFRαβ+CDH11+ cells were not significantly different
after PSL or MTX therapy (Figures 3D,E), although biological
drug therapy was associated with a significantly lower percentage
of pPDGFRαβ+CDH11– cells (P = 0.0332; Figure 3E).
Increased pPDGFRαβ Expression in
RA-FLSs After PDGF-BB, TGF-β, and
TNF-α Stimulation
PDGF-BB and TGF-β (2GF) stimulation with or without TNF-
α were performed to reproduce the pPDGFRαβ-predominant
environmental characteristic of RA-FLSs in vitro. PDGF-BB,
TGF-β, and TNF-α are typical factors that exacerbate the
pathology of RA. Because 2GF + TNF stimulation conferred
aggressive phenotypes to FLSs with elevated expression of IL-
6, IL-8, and other inflammatory cytokines and factors such as
MMP3 (20, 21), we hypothesized that 2GF + TNF-α would
increase the expression level of pPDGFRαβ in FLSs. The number
of live cells did not differ between 2GF and 2GF + TNF
(10 ng/mL or 100 ng/mL) stimulation of FLSs (P = 0.0631;
Supplemental Figure 4). Immunostaining against pPDGFRαβ
and CDH11 was performed to examine pPDGFRαβ and CDH11
expression after 2GF and 2GF+ TNF stimulation (Figure 4). In-
cell enzyme-linked immunosorbent assays were also performed
to quantify CDH11 and pPDGFRαβ expression. Stimulation
with PDGF-BB significantly increased CDH11 and pPDGFRαβ
expression compared to that without stimulation and 2GF +
TNF stimulation (Figures 4, 5A). Stimulation with 2GF + TNF
(100 mg/mL) significantly decreased CDH11 expression, but did
not significantly affect pPDGFRαβ expression (P = 0.002 and
P = 0.9123, respectively; Figures 4, 5A). Further, stimulation
with 2GF + TNF increased the pPDGFRαβ/CDH11 ratio in a
TNF-concentration-dependent manner versus 2GF stimulation,
making pPDGFRαβ expression predominant (Figures 5B,C;
P < 0.0001). Because 2GF stimulation caused predominant
CDH11 expression, 2GF stimulation appeared to generate a
phenotype similar to FLSs in a state of acute inflammation.
This is because, during acute inflammation, the synovium
exhibits increased CDH11-positive cells, but few cells expressing
pPDGFRαβ (17). Further, because 2GF + TNF stimulation
increased the pPDGFRαβ/CDH11 ratio, this was thought to
represent a phenotype that resembled pPDGFRαβ+CDH11–
cells that accumulate in the RA-SL in vivo.
Effects of the TNF Inhibitor, Etanercept
Concomitant TNF and 2GF stimulation caused predominant
pPDGFRαβ expression in FLSs, suggesting that TNF-α inhibited
CDH11 expression, but did not affect pPDGFRαβ expression
in the FLSs. Next, we investigated whether a TNF inhibitor
(etanercept), most commonly used in RA therapy, could restore
the pPDGFRαβ/CDH11 ratio after 2GF + TNF stimulation
(Figure 6). Adding etanercept to FLSs stimulated with 2GF +
TNF did not lead to a significant decrease in the number of
live cells, according to WST-8 assays (P = 0.979; Figure 7A).
Further, adding etanercept did not reduce the total cell count
(P = 0.247; Figure 7B). However, etanercept at a concentration
of 50µg/mL significantly reduced pPDGFRαβ expression (P
= 0.0056; Figure 7C), and that at a concentration of 25 or
50µg/mL significantly reduced the pPDGFRαβ/CDH11 ratio
(P = 0.00294 and P < 0.001, respectively; Figure 7D). Since
a TNF inhibitor could reduce the pPDGFRαβ expression and
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FIGURE 3 | Reduced TNF-R1 expression in the RA-SL was associated with a longer RA duration and the use of prednisolone (PSL). Correlations between the rate of
TNF-R1 positivity in the SL and (A) the age of RA patients and (B) RA duration. Although the TNF-R1 positivity rate did not correlate with age, a negative correlation
with RA duration was observed. (C–E) the TNF-R1-positive rate in the SL was compared with the percentages of pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, and
pPDGFRαβ+CDH11+ cells, depending on whether methotrexate (MTX) or biological drugs were used. (C) although the use of PSL reduced TNF-R1 expression in the
SL, significant differences were not observed in the percentages of pPDGFRαβ+CDH11–, pPDGFRαβ-CDH11+, or pPDGFRαβ+CDH11+ cells. (D) MTX use was
(Continued)
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FIGURE 3 | not associated with significant differences in the TNF-R1 expression rate or in the percentages of any of the cell populations. (E) the TNF-R1 expression
rate did not differ significantly with the use of biological drugs, although a significant decrease in pPDGFRαβ+CDH11– cells was observed. Correlations were
examined statistically by using Pearson’s correlation coefficient, and unpaired t-test was used to compare the effects of drugs. The significance level was P < 0.05.
FIGURE 4 | pPDGFRαβ and CDH11 expression by PDGF-BB, TGF-β, and TNF-α stimulation of RA-FLS. The effects of PDGF-BB, TGF-β stimulation alone, PDGF-BB
and TGF-β (2GF) stimulation, 2GF + 10 ng/mL TNF, and 2GF + 100 ng/mL TNF stimulation on RA-FLSs were investigated. Representative images of immunostaining
for pPDGFRαβ (green) and CDH11 (red) expression with FLSs stimulated with PDGF, TGF-β, and TNF in each combination.
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FIGURE 5 | PDGF-BB, TGF-β, and TNF-α stimulation of RA-FLS resulted in
predominant pPDGFRαβ expression. (A–C) quantitative data for pPDGFRαβ
and CDH11 expression obtained by performing in-cell ELISAs. Stimulation
with TNF in addition to 2GF reduced CDH11 expression, but not pPDGFRαβ
expression. Stimulation with 2GF reduced the pPDGFRαβ/CDH11 ratio and
elevated CDH11 expression. Stimulation with 2GF + TNF caused
concentration-dependent increases in the pPDGFRαβ/CDH11 ratio and
elevated pPDGFRαβ expression. One-way ANOVA was used for statistical
analysis, and the Tukey–Kramer method was used to compare the groups.
The significance level was P < 0.05. *P < 0.05; **P < 0.01.
pPDGFRαβ/CDH11 ratio, this drug could suppress FLSs with
pPDGFRαβ expression, which is thought to have an aggressive
phenotype that contributes to RA.
Effects of the CDK4/6 Inhibitor, Palbociclib
While the TNF inhibitor caused a reduction in the
pPDGFRαβ/CDH11 ratio, it had no effect on the cell count.
We confirmed an excess accumulation of cells in the SL
of the synovium of patients with RA in vivo (Figure 1A).
This finding indicates that, in addition to changing the
FLS phenotype, reducing the cell count is essential for RA
therapy. The cell senescent factor p16 exhibited reduced
expression in the accumulated cells in vivo (Figures 2A,B).
Because p16 negatively regulates CDK4/6 (25), we surmised
that reduced p16 expression in RA synovial tissue results
in elevated expression of CDK4/6. Reduced p16 expression
and increased CDK4/6 expression are often observed in
cancer cells and cancer-associated fibroblasts (CAFs) in
breast cancer and head and neck cancer and can induce
hyperproliferation and cancer cell spread (27, 28). Further,
CDK4/6 inhibitors can effectively suppress cell proliferation and
the epithelial-mesenchymal transition (EMT) (22). Therefore,
we investigated whether the CDK4/6 inhibitor palbociclib
would reduce the number of FLSs (Figure 6). When palbociclib
was added at a concentration of 7.5µM or 15µM to FLSs
stimulated with 2GF + TNF, significant reduction in the
number of live cells (P = 0.0204 and P = 0.0007, respectively;
Figure 7A) and reduction in the total cell count (P < 0.0001
and P < 0.0001, respectively; Figure 7B) were observed in
WST-8 assays. Adding palbociclib significantly decreased the
total expression level of pPDGFRαβ and CDH11, but did not
significantly decrease the pPDGFRαβ/CDH11 ratio and the
pPDGFRαβ and CDH11 expression level per cell (Figures 7C,D,
Supplemental Figure 5). These findings showed that CDK4/6
inhibition could suppress FLS proliferation and reduce the
cell count; therefore, palbociclib can be expected to exert a
therapeutic effect on accumulated cells.
Effects of Combination Treatment With a
TNF Inhibitor and a CDK4/6 Inhibitor
To treat an increased number of FLSs that become pPDGFRαβ-
predominant owing to 2GF + TNF stimulation, we investigated
the combined effects of a TNF inhibitor (which reduced the
expression of pPDGFRαβ) and a CDK4/6 inhibitor (which
reduced the cell count; Figure 6). WST-8 assays showed that
the cell count did not decrease significantly (P = 0.0783;
Figure 7A), although a reduction in the total cell count
was observed when in-cell enzyme-linked immunosorbent
assays were performed (P < 0.001; Figure 7B). Moreover,
the combination treatment with etanercept and palbociclib
significantly decreased the total expression level of pPDGFRαβ
and CDH11 (P < 0.0001; Figure 7C), but a significant difference
in the pPDGFRαβ/CDH11 ratio (which was observed with a TNF
inhibitor alone) was not found with combination treatment (P
= 0.916; Figure 7D). The effects of combined treatment with a
CDK4/6 inhibitor and a TNF inhibitor were similar to those of
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treatment with the CDK4/6 inhibitor alone, which indicates that
including a TNF inhibitor had little effect.
DISCUSSION
FLSs play a role in themaintenance of homeostasis of the synovial
fluid and a healthy synovium. In the case of acute inflammation
such as due to injury, FLSs are activated; they proliferate and
mobilize immune cells in the early stages of inflammation,
exerting anti-inflammatory effects as inflammation subsides
and participating in synovial remodeling by producing the
extracellular matrix (ECM). FLSs are essential for maintaining
and regenerating the synovium (11, 18). Nonetheless, while FLSs
are activated and proliferate during chronic inflammatory states
such as RA, they also acquire an aggressive phenotype with
strong invasive properties and release ECM-degrading enzymes,
thereby causing joint destruction (4, 7, 10, 17). In this study,
we compared the FLS phenotypes activated during chronic
inflammation in the synovium of patients with RA and those
with injuries. In the LL, the percentage of pPDGFRαβ+CDH11–
cells did not differ between the groups. In the SL, the percentage
of pPDGFRαβ+CDH11– cells was higher in the RA group.
Moreover, pPDGFRαβ+CDH11– cells exhibited resistance to
cell death. Based on these observations, we hypothesized that
the pPDGFRαβ+CDH11– cells in the RA-SL contributed to
treatment resistance in patients with RA. Therefore, we examined
the phenotypes of pPDGFRαβ+CDH11– cells in detail and
identified the methods to control them.
Previous studies have shown that FLSs in the LL of RA
synovial tissue exhibit pannus formation, produce MMPs and
other substances, and have a direct effect on joint destruction.
SL FLSs have been indicated as a possible reservoir important
for supplying FLSs to the LL (7, 29). LL FLSs exhibit expression
of cell-adhesion factors such as CDH11 and gp38, whereas
SL FLSs express different markers such as CD90 and CD248
(7). Cells that express gp38 and CD248 have been reported
to be highly sensitive to TNF-α (7, 8). The different cellular
functions of FLSs in the LL and SL indicate that different
therapies could be effective against FLSs. In this study, CDH11
and pPDGFRαβ expression was observed in both the LL and
SL of RA synovium and acutely inflamed synovium, although
we found that a larger number of pPDGFRαβ+CDH11– cells
was specific to the RA-SL. In general, PDGFR+ cells in the
synovium regulate synovial growth and invasion, anchorage-
independent growth, and collagenase transcription in response
to PDGF stimulation (17, 30). Moreover, the activation of PDGF
signaling can promote cell survival and resistance to apoptosis
via the PI3K–Akt pathway (14). pPDGFRαβ is activated when
PDGF stimulates PDGFR (17), suggesting that the pPDGFRαβ+
cells identified in this study participated in synovial growth
and invasion and accumulated in the synovium. In fact, the
pPDGFRαβ+CDH11– cells that were observed in large numbers
in the RA-SL were TNF-R1-negative, p16-negative, and Bcl-2-
positive. TNF-R1 possesses a death domain and is characterized
by an ability to induce apoptosis by activating caspase (26).
In fact, the RA-SL exhibited reduced TNF-R1 expression (31),
which is thought to inhibit cell death. Interestingly, the TNF-R1-
positive rate in SL synovial cells was correlated negatively with
the duration of RA in patients (Figure 3B). That is, prolonged
affliction with RA was associated with reduced TNF-R1, which
reduces the sensitivity to TNF-α. Thus, the synovium of patients
with long-term RA would exhibit reduced TNF-R1 expression
to help maintain chronic inflammation and promote fibrosis,
which would inhibit cell death and cause cells to accumulate.
p16 is an important factor in cell senescence that inhibits cell
proliferation by suppressing cell cycle progression via the p16–
Rb pathway (25). Reduced p16 is observed in breast cancer
and other CAFs, and cells with reduced p16 expression are
known to hyperproliferate and accumulate in tissues. (27) p53
suppresses cell cycle progression and promotes cell death via
the p53–p21 pathway (25). Increased p53 expression in the
synovium of RA causes mutations that are reported to suppress
normal p53 functions in a dominant-negative manner (32, 33).
As reported in this and other studies, while p53 expression is
elevated, cell proliferation is not suppressed, which leads to the
accumulation of cells in the synovium, suggesting that elevated
p53 in the RA synovium does not function normally. Bcl-2 is
involved in controlling apoptosis in the mitochondria, and Bcl-2
expression in FLSs has been correlated with synovial hyperplasia
and inflammation (34). Bcl-2 expression has been observed in
RA-FLSs and is thought to be associated with apoptosis resistance
(26). The above findings indicate that pPDGFRαβ+CDH11–
cells are resistant to cell death and are characterized by a tendency
to accumulate in the synovium, suggesting that they are resistant
to treatment. In contrast, pPDGFRαβ+CDH11+ cells, or cells
that despite being pPDGFRαβ+ also express CDH11, exhibited
an interesting feature of increased TNF-R1 and p16 expression.
CDH11 expression was observed in FLSs in healthy synovium;
in addition to being involved in maintaining the shape of the
synovium, CDH11 was involved in inflammation, which leads
to an increase in its expression (5). CDH11 is considered an
adhesion factor involved in calcium-dependent cell–cell adhesion
(35), and elevated CDH11 expression in tumor cells can suppress
tumor formation by inducing tumor cell apoptosis, suppressing
EMT, and reducing stemness (36). Further, suppressing CDH11
expression can exacerbate the proliferation and invasion of
head and neck cancer cells (37). Thus, CDH11 in tumor cells
plays important roles in suppressing proliferation and invasion.
Conversely, the expression of CDH11 has been reported to
activate tumor cells such as breast cancer (38). In FLSs from
patients with RA, CDH11 has been shown to promote the
production of IL-6 and secretion of proinflammatory factors via
the MAPK and NFκB signaling (39). Many of the functions of
CDH 11 have not yet been elucidated, and further investigation
is required in this regard. The phenotypes of aggressive RA-FLSs
can have tumor-like attributes in terms of excessive proliferation,
invasion, and migration capacities (10, 20), suggesting that
suppressing pPDGFRαβ expression and promoting CDH11
expression in FLSs could be an effective treatment strategy for
RA. Further, reducing the number of FLSs that accumulate
specifically in the RA-SL is necessary.
We conducted an in vitro experiment to identify effective
therapies related to pPDGFRαβ and CDH11 expression in FLSs.
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FIGURE 6 | pPDGFRαβ and CDH11 expression by 2GF + TNF and a TNF inhibitor (etanercept) and a CDK4/6 inhibitor (palbociclib) in RA-FLSs. Representative
images of immunostaining for pPDGFRαβ and CDH11 expression with FLSs stimulated with 2GF + TNF and the TNF and CDK4/6 inhibitors in each combination.
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FIGURE 7 | Etanercept suppressed pPDGFRαβ expression in RA-FLSs stimulated with 2GF + TNF, and palbociclib reduced the cell count. (A) cell proliferation assay
and (B–D) quantitative cell count and pPDGFRαβ/CDH11 ratio data obtained by performing in-cell ELISAs with FLSs stimulated with 2GF + TNF and exposed to
different concentrations of etanercept and palbociclib. Adding etanercept to FLSs stimulated with 2GF + TNF did not significantly decrease the number of live cells,
but significantly reduced the pPDGFRαβ/CDH11 ratio. Adding palbociclib significantly reduced the number of live cells, but did not significantly change the
pPDGFRαβ/CDH11 ratio. Etanercept + palbociclib significantly reduced the number of live cells, but did not significantly change the pPDGFRαβ/CDH11 ratio.
Dunnett’s test was used to statistically analyze differences occurring with 2GF + TNF stimulation. The significance level was P < 0.05. *P < 0.05; **P < 0.01;
***P < 0.001.
Rosengren et al. (20) increased the synergistic response of
FLSs by including 2GF stimulation in vitro and showed that
the addition of TNF-α increased the production of IL-6, IL-
8, and MMP3. Similarly, Shibuya et al. (21) stimulated FLSs
with 2GF + TNF, which increased PI3Kδ expression and led
to synovial hyperplasia by activating the PI3K–Akt pathway. In
other words, the phenotype obtained by stimulating FLSs with
2GF + TNF resembled that of the pPDGFRαβ+CDH11– cells
that were observed in vivo. Based on the pPDGFRαβ/CDH11
ratios, we found that stimulating FLSs obtained from RA with
2GF caused the ratio to decrease, whereas stimulation with 2GF
+ TNF caused it to increase. PDGF-BB, TGF-β, and TNF-
α are abundant in the synovial environment of patients with
RA (40, 41). Increased expression of PDGF-B and TGF-β has
been reported during acute inflammation of the synovium,
such as due to injury (42). Further, TNF-α expression is
known to be stronger in RA synovium compared to that in
the synovium during acute inflammation (41). Accordingly,
in vitro 2GF + TNF stimulation is thought to be a reliable
model that accurately reflects the synovial environment of
RA and is useful for assessing the therapeutic effects against
pPDGFRαβ+CDH11– cells. We found that a TNF inhibitor
reduced the pPDGFRαβ/CDH11 ratio, which was elevated by
2GF + TNF stimulation. We believe that the decrease in the
pPDGFRαβ/CDH11 ratio occurred because the TNF inhibitor
suppressed TNF signaling and interactions between PDGFR and
CDH11 occurred. In a previous study, TNF-α stimulation was
shown to increase PDGFR expression via MAPK and c-Src (43).
Moreover, although the detailed mechanism remains unclear,
TNF-α stimulation has been reported to create a feedback loop
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in which increased Rsk2 expression suppresses TNF signaling
and CDH11 expression (44). In fact, TNF inhibitors have been
shown to have high efficacy against RA in humans by suppressing
TNF-α and inducing cell death in FLSs (45). SL fibrosis has been
reported to occur when TNF inhibitors are used in RA therapy
(12). Although TNF inhibitor therapy can be expected to prevent
cell accumulation, it might only marginally affect pre-existing cell
accumulation (46).
We believe that reducing the accumulated FLSs is essential
for successful RA therapy. In this study, excessive cell
accumulation was noted in the SL, and many of these cells
were pPDGFRαβ+CDH11–. Moreover, the percentage of p16-
positive pPDGFRαβ+CDH11– cells was low. The p16 protein
inhibits cell proliferation by suppressing cell cycle progression
and negatively controlling CDK4/6 (25). Therefore, we surmised
that suppressing CDK4/6 would inhibit the proliferation
of pPDGFRαβ+CDH11– cells. A large-scale genome-wide
association study showed that CDK4/6 was a risk gene for RA,
raising the possibility that CDK4/6 inhibitors could be effective
therapeutics for RA (47). Moreover, the CDK4/6 inhibitor
palbociclib suppressed arthritis in RA animal models (23, 48).
Therefore, we hypothesized that palbociclib could potentially
suppress FLS proliferation and reduce the cell count, both of
which were confirmed experimentally. However, palbociclib was
not found to reduce the pPDGFRαβ/CDH11 ratio. Next, we
tested combination treatment with a TNF inhibitor and CDK4/6
inhibitor, which decreased the cell count, but did not decrease the
pPDGFRαβ/CDH11 ratio. Administering CDK4/6 for treating
breast cancer has been reported to increase TNF-α production
and antigen presentation (49). In this study, the effects of CDK4/6
might have amplified the action of TNF-α to mask the effects of
the TNF inhibitor.
The interesting finding of this study was the cell population
that characteristically showed increased pPDGFRαβ+CDH11–
expression in the RA SL. pPDGFRαβ+CDH11– cells exhibit cell
death resistance and abnormal proliferation, which suggests a
tendency to accumulate in the synovium. Other reported FLS
markers include CD90, CD248, and gp38 (7, 8). We were unable
to determine whether the pPDGFRαβ+CDH11– cells identified
in this study differed from cell populations identified with
other makers. However, we believe that pPDGFRαβ+CDH11–
cells were almost mesenchymal cells because, among the
total 8.3% pPDGFRαβ+CDH11– cells, 1.3% were CD45+
hematopoietic cells, the percentage of which was very small
(Supplemental Figure 2). Furthermore, cells that express gp38
and CD248 have been reported to be highly sensitive to TNF-
α (8, 50), indicating that they were different cell populations
than pPDGFRαβ+CDH11– cells, which have low TNF-R1
expression. Moreover, CD90 is found not only in RA-FLSs,
but is a cell-surface marker that is also widely expressed in
normal FLSs (19), suggesting a high likelihood of expression in
pPDGFRαβ+CDH11– cells. The pPDGFRαβ used in this study
was activated by PDGF signaling. Previous studies have shown
that suppressing PDGFR suppresses FLSs (17), indicating that
pPDGFRαβ is amarker that is intimately related to FLS functions.
Further, the control samples used in this study were obtained
from post-traumatic synovium, such as after fracture or an ACL
injury. We used post-traumatic synovium because our objective
was to compare synovium in the acute and chronic inflammatory
states to clarify the characteristics of the cells that accumulated.
With post-traumatic synovium, the control group was younger
and contained more men than in the RA group, indicating
that the groups were not matched for age or sex. Nevertheless,
the percentages of cells expressing pPDGFRαβ and/or CDH11
in this study did not correlate with age or sex (Figures 1E–G,
Supplemental Figure 6). Thus, although we cannot rule out the
influence of age or sex, the increase in pPDGFRαβ+CDH11–
cells in the RA-SL might not have been affected by age or sex
and was highly likely a cause of pathology in RA. In this study,
we also found that TNF inhibitors increased the expression
level of CDH11. Such an increase appeared to decrease Bcl-2
expression and increase p16 expression, thereby suppressing the
resistance to cell death and causing excessive cell proliferation
of RA-FLSs. Although TNF inhibitors exert a strong therapeutic
effect clinically, treatment-resistant cases are common (3). In
particular, while TNF inhibitors are reported to act on the LL,
they tend to have less effect on the SL (9). Because the cells
targeted in this study are abundant in the SL, enabling the
pharmacological effects of TNF inhibitors to reach the SL could
be important for maximizing their therapeutic effects. Future
in vivo experiments are warranted to identify effective therapies
that target pPDGFRαβ+CDH11– cells accumulating in the SL,
including the examination of drug delivery to the SL.
In this study, we showed that pPDGFRαβ+CDH11– cells
accumulated specifically in the SL of the synovium in RA, and
that their resistance to cell death could lead to the accumulation
of synovial cells and resistance to treatment. Stimulation with
2GF + TNF caused the cells to remain in a pPDGFRαβ-
predominant state, similar to the pPDGFRαβ+CDH11– cells
observed in RA-SL, which indicates that therapies that are
effective against these cells could lead to treatments for cells
accumulated in the synovium. Clarifying the characteristics of
treating FLSs with TNF or CDK4/6 inhibitors and using drugs
in ways that are adapted to the pathology of the synovium could
lead to better therapeutic effects.
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Supplemental Figure 1 | The quantitative data show the cell density of
pPDGFRαβ+CDH11−, pPDGFRαβ−CDH11+, and pPDGFRαβ+CDH11+ cells.
The cell densities of pPDGFRαβ+ CDH11−, pPDGFRαβ−CDH11+, and
pPDGFRαβ+CDH11+ cells in the LL were not different between RA and control
groups. However, their densities in the SL were significantly higher in the RA
group. An unpaired t-test was used for statistical analysis. The significance level
was P < 0.05.
Supplemental Figure 2 | The percentages of cells expressing pPDGFRαβ,
CDH11, and CD45. Representative images of pPDGFRαβ, CDH11, and CD45
staining and the percentages are shown in the pie chart.
Supplemental Figure 3 | Comparison between the RA and the control group for
quantitative expression data for Bcl-2 and p16 in 3 cell populations
(pPDGFRαβ+CDH11−, pPDGFRαβ−CDH11+, pPDGFRαβ+CDH11+ cells) in
the SL of the synovium. One-way ANOVA was used for statistical analysis. The
significance level was P < 0.05.
Supplemental Figure 4 | Cell proliferation assay by using PDGF-BB, TGF-β, and
TNF-α stimulation of RA-FLS. The stimulation with PDGF-BB, TGF-β, and TNF-α
stimulation did not show significant difference in RA-FLS. One-way ANOVA was
used for statistical analysis. The significance level was P < 0.05.
Supplemental Figure 5 | Normalized expression of pPDGFRαβ and CDH11
expression by using 2GF + TNF, and etanercept and palbociclib in RA-FLSs.
(A,B) Normalized expression of pPDGFRαβ and CDH11 in RA-FLSs stimulated
with PDGF-BB, TGF-β, and TNF-α in each combination. (C,D) Normalized
expression of pPDGFRαβ and CDH11 in RA-FLSs stimulated with 2GF + TNF,
and etanercept and palbociclib in each combination. One-way ANOVA was used
for statistical analysis. The significance level was P < 0.05.
Supplemental Figure 6 | Correlation between the percentages of cells
expressing pPDGFRαβ and/or CDH11, and the characteristics of patients. The
percentages of cells expressing pPDGFRαβ and/or CDH11 did not correlate with
age or sex. Correlations were examined statistically by using Pearson’s correlation
coefficient. The significance level was P < 0.05.
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